Nyxoah SA (NASDAQ:NYXH) is set to release its Q2 2025 earnings on Aug 18, 2025. The consensus estimate for Q2 2025 revenue is ...

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

Analysts estimate that Nyxoah will report an earnings per share (EPS) of $-0.63. Nyxoah bulls will hope to hear the company ...

Nyxoah NYXH recently received FDA approval for its Genio system, an innovative therapy for moderate to severe Obstructive Sleep Apnea (OSA). Featuring a leadless, battery-free design powered by an ...

Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S.

Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...

The FDA has approved the Genio® system for treating patients with moderate to severe obstructive sleep apnea (OSA) with an ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

Nyxoah Reports Fourth Quarter and Financial Year 202 4 Financial and Operating Results FDA PMA Application Review Nearing Conclusion Positioned for U.S. Commercial Launch in March 2025. Revenue ...

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

Nyxoah said the FDA approved the company's Genio system for a subset of patients with moderate to severe obstructive sleep apnea. The system includes a wearable component, which provides patients with ...